Intercept’s OCA Facing Extended Approval Wait In NASH As Known Risks Swamp Uncertain Benefits

 
• By Sue Sutter
  
cloudy horizon
Panel vote suggests any approval of OCA for NASH will be far in the distance. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US FDA Performance Tracker

More from Regulatory Trackers